Rapport Therapeutics COO Gault sells $281k in stock

COO Cheryl Gault sold 10,000 RAPP shares for $281,857 on March 30, 2026 (two tranches at weighted averages $28.0401 and $28.5530) under a Rule 10b5-1 plan; she now directly owns 159,914 shares. RAPP stock has surged 176% over the past year and trades at $31.29, though InvestingPro flags it as overvalued. Rapport reported FY2025 results and released positive Phase IIa RAP-219 data, and plans to initiate two Phase 3 focal onset seizure studies in Q2 2026 after a successful end-of-phase-2 FDA meeting. Multiple brokers (Truist, Stifel, Jones Trading) reiterated Buy (PTs $44, $56, $50) and BTIG maintained Buy while raising its PT from $47 to $53.

Analysis

The programmatic shift from discovery/early development to registration-mode converts valuation drivers from speculative science to operational execution. Markets will reprice the equity based on enrollment velocity, site activation cadence, and interim-safety signals rather than preclinical promise, so month-to-month enrollment metrics will matter more than headline biology.

This re-risking creates a new set of bottlenecks: CRO capacity, sourcing of clinical supply, and investigator bandwidth become first-order value drivers; surprises in any of these areas (delays, cost overruns, competing trials) can induce meaningful negative revisions to probability-of-success and force financing or dilution. Conversely, clean, accelerating enrollment or a favorable interim safety readout would rapidly compress perceived trial risk and attract strategic acquirers seeking near-term registration assets.

Analyst optimism and bullish narratives create asymmetric exposure: upside is capped by binary approval/M&A outcomes while downside is governed by the common small-cap clinical-pathway risks (safety issues, failed endpoints, cash runway). Insider liquidity programs — even when pre-arranged — add a predictable, low-friction supply overhang that can mute upside during momentum runs and amplify drawdowns on negative operational news.

Given the above, the tradeable regime is tactical and event-driven. Focus execution around operational milestones (monthly enrollment, interim analyses, manufacturing ramps) and structure risk so that capital is preserved through binary readouts while retaining upside participation in a successful execution or strategic exit.

Key Decisions for Investors

• Buy RAPP stock size = 1-2% NAV with a protective put: purchase shares and buy 6-9 month 25-30% OTM puts to cap downside; R/R: asymmetrical — limited left-tail (defined by put cost) versus 30-60% upside if enrollment trends and interim safety remain clean.
• Call-spread exposure for leveraged upside with limited cost: buy a 12-month call spread (buy lower strike, sell higher strike ~2x that strike distance) to capture upside into potential interim readouts or M&A interest; max loss = premium paid, target 2-3x payback if program derisks.
• Pair trade to hedge category risk: long RAPP (0.75% NAV) / short an epilepsy-focused small-cap peer (eg MRNS or ACAD) (0.75% NAV) to isolate company-specific execution; objective is to monetize company-level operational execution while hedging broader antiseizure sentiment shocks.
• Event-driven short or put-buy ahead of expected operational misses: if monthly enrollment metrics lag or a CRO/provider issue is reported, buy near-dated puts (4-8 weeks) to capture 20-40% downside spikes; size modest (0.5% NAV) due to timing risk.
• Prepare liquidity watchlist and size discipline: set automatic trim at +40-60% from current levels and require re-underwriting of base-case probabilities if cash runway extension or dilution is announced — treat any financing as a sell signal until enrollment trajectory is validated.